IL-1β promotes cervical cancer through activating NF-κB/CCL-2

xlomafota13 shared this article with you from Inoreader IL-1β promotes cervical cancer through activating NF-κB/CCL-2 Via International Journal of Clinical and Experimental Pathology Int J Clin Exp Pathol. 2021 Apr 15;14(4):426-433. eCollection 2021. ABSTRACT Cervical cancer is a malignancy with high morbidity and mortality among women. Interleukin (IL)-1β, chemokine (C-C motif) ligand 2 (CCL-2), and activation of NF-κB have been proven to be closely related to the progression of various tumors. However, their role in cervical cancer remains unclear. Cell proliferation, migration, and invasion were detected using MTT, wound healing, and transwell assays. Western blotting and qRT-PCR were used to measure expression of target genes. IL-1β greatly promoted the release of CCL-2 from HeLa cells. Activation of NF-κB and phosphorylated NF-κB (p65) nuclear translocation were accelerated by IL-1β. TPCA-1, a blocker of NF-κB, significantly inhibited the release of CCL-2 from HeLa cells. TPCA-1 markedly reversed the promotional effect of IL-1β on viability of HeLa cells. IL-1β increased the cell migration, proliferat ion, and invasion of HeLa cells through targeting the NF-κB/CCL-2 pathway. IL-1β/NF-κB/CCL-2 might be a promising treatment target for cervical cancer treatment and prevention. PMID:33936364 | PMC:PMC8085834 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.